anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
Observational epidemiologic studies have observed an inverse relationship between daily dietary magnesium intake and blood pressure. Except for blood pressure, magnesium may also beneficially affect other cardiovascular risk markers. Whether all these effects translate into improved vascular function is not known. Different vascular function markers at various stages on the pathway between diet and disease exist. One of these markers, vascular stiffness, is closely related to the process of atherosclerosis, an independent cardiovascular risk factor, and predictive of future cardiovascular events and mortality. A recently published intervention study showed that oral magnesium citrate supplementation of 350 mg per day for 24 weeks was well-tolerated and improved vascular stiffness by 1.0 m/s. Importantly, it was not established whether the beneficial effect on vascular stiffness was due to the supplementation of magnesium or due to citrate. This may involve effects on gut microbiota and systemic metabolic effects. The current study was designed to (1) reproduce the result of the earlier study and to (2) investigate whether there is a difference between different commonly used magnesium salts (magnesium citrate, magnesium sulphate and magnesium oxide) in terms of effects on vascular stiffness, blood pressure and gut microbiota.
This is a hospital-based retrospective cohort study and the Immunohematologic characteristics of COVID-19 patients will be investigated systematically. In this study, we will seek to understand the association between SARS-CoV-2 infection and blood groups and explore the Anti-A and Anti-B effects in COVID-19 patients with graded severity. We will analyze the transfusion requirement and the clinical recurrences of COVID-19 patients. The discrepancy of blood group phenotypes in COVID-19 patients with graded severity will be also analyzed on the molecular level. This retrospective cohort study was conducted using electronic health recording data in Tongji Hospital. The clinical characteristics for all eligible patients will be retrieved. The records will be verified to avoid possible bias. Data collection was carried out independently by two investigators and reviewed by two different investigators.
We will enroll 60 smokers who will complete four lab sessions and two field assessments. Participants meeting initial eligibility criteria over the phone will complete an in-person screening visit. Breath carbon monoxide and alcohol tests will be collected. Participants will answer questionnaires on the computer and via interview about their tobacco use and medical history. Eligible participants will remain in the lab to complete additional baseline questionnaires and will be given the opportunity to sample alternative tobacco products, such as LCCs, smokeless tobacco, electronic cigarettes, and nicotine replacement.

During the next two lab sessions, participants will complete a behavioral economics assessment, the Experimental Tobacco Marketplace task, designed to simulate purchasing tobacco products online. Participants will be given 'coupons' to obtain tobacco products from the online experimental marketplace. After these lab sessions, participants will be provided with the tobacco products they selected from the online experimental marketplace to use during 3-day field assessments to validate the task. Participants will be told to only use tobacco products provided by the lab during the field assessments. At both lab sessions, participants will complete questionnaires about their tobacco use, mood, and reactions to the alternative tobacco products. At the final lab session, a qualitative interview will be conducted to learn more about the participants' experiences selecting and using tobacco products.
OBJECTIVE: Moyamoya disease (MMD) is a rare and progressive stenosis of cerebral arteries characterized by abnormally proliferative vasculopathy. Current studies have demonstrated that Neuregulin 1 (NRG1) plays a key role in angiogenesis-related disorders. Thus, the aim of our study is to investigate the serum NRG1 levels and their clinical correlations in MMD patients.
METHODS: In this study, thirty adult patients with MMD and age-gender matched healthy controls were enrolled from our hospital between July 2020 and April 2022. Peripheral blood samples were collected at baseline, and clinical data were obtained from the electronic medical record system. Serum NRG1 concentrations were measured by enzyme-linked immunosorbent assay. Sanger sequencing was applied to detect the RNF213 p.R4810K mutation.
RESULTS: The serum NRG1 levels were significantly higher in MMD patients compared to controls (14.48 ± 10.81 vs.7.54 ± 6.35mmol/L, p < 0.001). No statistical difference in baseline clinical characteristics was found between both groups. Correlation analyses showed that NRG1 levels were positively associated with Suzuki staging (r = 0.4137, p = 0.023) while not related to other clinical features (reduced cerebral blood flow, posterior cerebral artery involvement, bilateral or unilateral steno-occlusive changes). Furthermore, subgroup analysis revealed that MMD patients with the RNF213 p.R4810K mutation presented with significantly higher NRG1 levels than those without the mutation (9.60 ± 0.929 vs. 25.89 ± 4.338 mmol/L, p = 0.001).
CONCLUSIONS: Our study suggests that increased serum NRG1 levels may constitute a characteristic feature of MMD, indicating a potential positive correlation with disease progression and the presence of the RNF213 mutation. This positions NRG1 as a potentially crucial target for further studies aimed at comprehending the pathogenesis of MMD.
The children in the older control cohort are 6 months to 4 1/2 years old and provide standardized test results in the area of speech and language development at child ages 2 1/2, 3 1/2, and 4 1/2 years. They receive no treatment and no close monitoring. These families provide questionnaire information every three months until child age 24 months.
Participants will receive a 12-week psychoeducational programme on nutrition and PA. This programme includes 8 sessions divided into modules of 2 or 3 lessons each, covering topics such as the benefits of PA and sports, healthy eating habits, and health risks associated with a sedentary lifestyle. Sessions will be conducted by a dietitian and a clinical psychologist. At the end of the trial, control group participants will be offered the opportunity to participate in the same PA programme as the intervention group at no cost.
One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions.
Following initial exposure to HIV, infection is established through the rapid replication of a homogeneous strain of the virus. Preliminary studies of combination antiretroviral therapy show that it is possible to reduce circulating HIV RNA to below detectable levels at this phase. Sustained suppression of viral replication or viral eradication may be possible only before HIV has become integrated in the immune system and undergone a number of quasi species mutations. This study will assess the feasibility of interrupting the natural course of HIV infection by using antiretroviral therapy soon after initial infection.

Nelfinavir (NFV) and zidovudine/lamivudine (Combivir) treatment starts as soon as possible and at most, 7 days from the diagnosis of HIV infection, and continues for 104 weeks. After 4 weeks of therapy patients are randomized to begin receiving IL-2 therapy or to delay starting it until Week 48. Patients may choose not to receive IL-2 treatment and remain in the study. Patients have clinic visits to measure viral load every 4 weeks. At a final clinic visit, physical examinations and collection of semen, cervical fluid, blood, and saliva specimens are done. Eligible consenting patients have a tonsil biopsy. Patients are reimbursed for participation in this study.
Multiple myeloma is a cancer that evolves from a state known as Monoclonal Gammopathy of Undetermined Significance (MGUS), defined by parameters of M spike and bone marrow. After evolution to myeloma, patients may be asymptomatic, that is, without any endorgan disease of hypercalcemia, renal insufficiency, anemia or bone lesions. In asymptomatic myeloma (ASxM), there is no standard therapy. Thalidomide has been tried in patients with ASxM but with significant toxicity. The patients with ASxM are evaluable in terms of paraprotein measurements. TBL12 sea cucumber extract has been shown to have a number of antitumor properties preclinically, including antiangiogenesis and direct tumor cytotoxicity. TBL12 has been used by a number of patients as a food supplement without any toxicity detected. We thus propose to determine the clinical activity of this agent in patients with ASxM. Patients will be given TBL12 at the dose of 2 units of 20 mL each twice per day daily for one year and the effects on the paraprotein noted. Clinical effects seen will be correlated with any in vitro changes in angiogenesis in patient bone marrow samples. The results of this trial may form the basis for the use of this nontoxic agent in patients with the prodrome of or with other early cancers.
The utility model relates to a tooth socket which is used for hermetical medicine delivery for the tooth surface and the gum margin, and provides a tooth socket which can effectively prevent the medicine outflow and the saliva diluting, and is used for hermetical medicine delivery for the tooth surface and the gum margin. The utility model is especially suitable for liquid medicine, gel and paste applied on the tooth surface and the gum margin. The tooth socket is provided with an upper tooth socket, a lower tooth socket and a medicine adding duct. Both the upper and the lower tooth sockets are provided with tooth slots which are well matched with the shape of the upper and the lower dental arches of the human body. A circle of grooves are arranged at the inner side of each tooth slot wall in middle front and at the top end of the each tooth slot wall at the rear part of the upper and the lower tooth sockets, and filled with non-poisonous material of high swelling capacity. A small hole with a seal cover is formed in the center of the top of the lower tooth socket. When the liquid medicine, the gel and the paste are used, the seal cover can be opened to be connected with the medicine adding duct; one end of the medicine adding duct is connected with the small hole on the lower tooth socket, and the other end thereof is matched with a connector at the end of a syringe needle of an ordinary medical injector, namely, the medicine can be added by using the injector.
Twenty-two healthy male individuals to recruited in the study. Conducting a power analysis through G∗Power, considering a moderate effect size (f = 0.25), an alpha level of 0.05, and a power of 0.8. The outcome of this analysis indicated a required minimum sample size of 21 individuals. This study was used a randomized, repeated measures cross-over design. Muscle activation levels during maximum voluntary isometric contraction (MVIC) of each muscle (Upper trapezius, Middle trapezius, Lower trapezius, Serratus anterior) will be recorded to normalize muscle activation levels during closed kinetic chain exercises. Muscle activation levels will be evaluated with a surface electromyography device (Noraxon, Myomotion, USA).
Disclosed herein are cells that secrete insulin in a glucose-dependent manner. The cell line comprises insulin-secreting cells that have been transfected with a minigene construct comprising a nucleotide sequence encoding for glucagon-like peptide-1 (GLP-1). In preferred embodiments, the minigene construct is operatively associated with a promoter. The cell line may be used to treat diabetes or other conditions in which delivering insulin in a glucose-dependent manner would be advantageous, to investigate the function and development of pancreatic cells, and to test the efficacy of drugs that stimulate insulin secretion. The cells may be implanted in a mammal, or may be included in a device that resides exterior to the mammal, yet which delivers insulin to the mammal in response to the glucose level of a body fluid in contact therewith. The minigene construct may also be implemented in conjunction with an in vivo gene transfer approach.
OBJECTIVE: The lateral retrocanthal transorbital endoscopic approach (LRCTEA) facilitates trajectory to the middle fossa, preserving the lateral canthal tendon and thus avoiding postoperative complications such as eyelid malposition. Here, the authors sought to define the surgical anatomy and technique of LRCTEA using a stepwise approach in cadaveric heads and offer an in-depth examination of existing quantitative data from cadaveric studies.
METHODS: The authors performed LRCTEA to the middle cranial fossa under neuronavigation in 7 cadaveric head specimens that underwent high-resolution (1-mm) CT scans preceding the dissections.
RESULTS: The LRCTEA provided access to middle fossa regions including the cavernous sinus, Meckel's cave, and medial temporal lobe. The trajectories and endpoints of the approach were confirmed using electromagnetic neuronavigation. A stepwise approach was delineated and recorded.
CONCLUSIONS: The authors' cadaveric study delineates the surgical anatomy and technique of the LRCTEA, providing a stepwise approach for its implementation. As these approaches continue to evolve, their development and refinement will play an important role in expanding the surgical options available to neurosurgeons, ultimately improving outcomes for patients with complex skull base pathologies. The LRCTEA presents a promising advancement in skull base surgery, particularly for accessing challenging middle fossa regions. However, surgeons must remain vigilant to potential complications, including transient diplopia, orbital hematoma, or damage to the optic apparatus.
There will be a 1:1 randomization betweennirogacestat 100 mg BID or 100 mg QD during the 4day run-in period prior to starting belantamab mafodotin on Cycle 1 Day 1 (days -4 to -1). The cycle length for Cycles 1-3 is 21 days (3 weeks). Treatment with nirogacestat will be 100 mg BID continuously during each cycle for all subjects. Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3 and nirogacestat 100mg BID will be administered continuously on Days 1-21 of each cycle. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg. Pomalidomide was added, 2 mg to the 1.4 mg/kg and 1.9 mg/kg dose cohorts.
Significant drug interactions with lamotrigine are summarized in this section.

Uridine 5´-diphospho-glucuronyl transferases (UGT) have been identified as the enzymes responsible for metabolism of lamotrigine. Drugs that induce or inhibit glucuronidation may, therefore, affect the apparent clearance of lamotrigine. Strong or moderate inducers of the cytochrome P450 3A4 (CYP3A4) enzyme, which are also known to induce UGT, may also enhance the metabolism of lamotrigine.

Those drugs that have been demonstrated to have a clinically significant impact on lamotrigine metabolism are outlined in Table 13. Specific dosing guidance for these drugs is provided in the Dosage and Administration section [see Dosage and Administration (2.1)]. 

Additional details of these drug interaction studies are provided in the Clinical Pharmacology section [see Clinical Pharmacology (12.3)]. 

Effect of Lamotrigine on Organic Cationic Transporter 2 Substrates

Lamotrigine is an inhibitor of renal tubular secretion via organic cationic transporter 2 (OCT2) proteins [see Clinical Pharmacology (12.3)]. This may result in increased plasma levels of certain drugs that are substantially excreted via this route. Coadministration of lamotrigine with OCT2 substrates with a narrow therapeutic index (e.g., dofetilide) is not recommended.
Intervention of high-frequency, vigorous-intensity walking exercise will be given to subjects in this group. A personalized walking exercise program will be arranged and conducted individually. Exercise training will be prescribed as a 12-week program, with three 25-minute instructor-led sessions per week. In each session, there will be 5-min warm-up and cool-down, and 25 minutes of exercise time. If needed, there will be a 10-20 min break for the subject to get hydrated and rest. The intensity level will be set to 7.0 metabolic equivalents (METs), in which 1 MET refers to the metabolic rate during quiet sitting \[23\]. During the training session, the heart rate will be continuously monitored by Polar E68 HR Sensor to make sure the subject meet the exercise intensity. 10 bpm fluctuation of the heart rate is acceptable \[24\].
PROBLEM TO BE SOLVED: To obtain the subject new compound shown by a specific formula, having blood coagulation factor Xa inhibitory activity, thus useful as a preventive/therapeutic agent for diseases due to thrombus, embolism, etc. SOLUTION: This new compound is shown by formula I (Ar is benzene ring or a heteroaromatic ring bearing 1 to 3 heteroatom(s); Q is a 3-7C alkylene, alkenylene or alkynylene; Y is a 5- to 10-membered monocyclic or bicyclic heterocyclic group bearing at least one N (atom), e.g. (E)-2-(7-amidino-2- naphthyl)-5-(isoindolin-5-yl)-4-pentenonic ethyl ester dihydrochloride. This compound of formula I is obtained, pref., for example, by reaction of a compound of formula II with hydrogen chloride directly in an alcohol solvent. The compound of formula II is prepared, pref. by uncleophilic substitution reaction between a compound of formula III and a compound of formula IV.
To provide a disinfectant composition that exhibits a high disinfecting effect even though it contains no or little alcohol.SOLUTION: A liquid disinfectant composition includes an organic acid and a surfactant as disinfecting components. The organic acid is at least one selected from the group consisting of adipic acid, fumaric acid, succinic acid, tartaric acid, malic acid, gluconic acid, and lactic acid. In the liquid disinfectant composition, the total amount of the organic acid is 0.2 mass% or more and 1 mass% or less. The surfactant is at least one selected from the group consisting of polyglyceryl fatty acid ester and sucrose fatty acid ester. In the liquid disinfectant composition, the total amount of the surfactant is 0.01 mass% or more and 5 mass% or less. The liquid disinfectant composition also includes water, or an alcohol-containing aqueous solution with a concentration of 10 mass% or less. The liquid disinfectant composition has a pH of 3.0 or more and 4.0 or less.SELECTED DRAWING: Figure 1
PURPOSE:To give the effect of a thermal stimulus extending over a long time by providing a sheet, in which a material having a medicinal component is impregnated, adjacently onto one surface of the bag of a throwaway body warmer, in which iron powders are contained as effective components. CONSTITUTION:For the throwaway body warmer to be used, every kind of body warmer can be used if only the iron powders 1 are contained in a bag 2 as the effective components. Further, for example, a litchi, a Rhodea japonica leaf, a Japanese cypress leaf, etc., can be mentioned as the material having a medicinal effect, and any type of the material out of a powder type, a chip type, and a type in which the medicinal component is extracted from the material having the medicinal effect and impregnated in a sheet 4 is available. It does not matter whether the bag 2 of the throwaway body warmer and a bag 5 in which the material having the medicinal effect or the sheet 4 is to be contained are unified or separated. Further, while the bag 2 and the bag 5 or the sheet 4 can be composed so that both of them can have the same size, it is desirable that the bag 5 or the sheet 4 is composed smaller than the bag 2. In this case, since the throwaway body warmer can be used under a state to prevent the medicinal component to volatilize from the bag 5 or the sheet 4 from escaping to an external part, the component with the medicinal component can act more remarkably.
Subjects apply placebo Viaskin® patch daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an oral food challenge (OFC) and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using the same 21-day graduated dosing period used in the blinded phase) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
PROBLEM TO BE SOLVED: To easily prepare a finding report by recognizing the inputted voice of finding contents and document-processing the recognizing result so as to prepare a finding reporting document. SOLUTION: A user fits a headphone 1, looks at an X-ray photograph itself of an X-ray photographic image displayed on a display 2 and inputs the finding contents by voice to a microphone 1a. Then a voice recognizing and synthesizing device 12 extracts a feature voice pattern from inputted voice to detect a coincident feature voice pattern in a term dictionary 16a on a hard disk 16. A character string obtained link this is voice-synthesized by the voice recognizing and synthesizing device 12 and reproduce-outputted by a speaker 1B. Further, the character string, that is a recognized character and attribute, obtained by the voice recognizing and synthesizing device 12 is delivered to a finding preparing program through an operation system(OS). On the other hand, information inputted from a keyboard 3 is delivered to the finding preparing program through OS.
The recipe is (pts. wt.): root of membranous milk vetch 10-80, acanthopanax senticosus 10-80 and and xingmao 20-90, glossy ganoderma 1-50, adenophora tetraphylla 1-50, and pseudo ginseng 1-50. The prodn. process is mixing thoroughly the above mentioned ingredients, and extracting (decoction) and then concentration. Said proprietary has the efficacies of tonifying the kidney, invigorating the function of the spleen, replenishing vital essence, nourishing the blood, strengthening the body resistance and/or restoring normal functioning of the body to consolidate the constitution, removing blood stasis, promoting tissue regeneration and prolonging life. It can be used for anti-senility, restoring the physical quality and preventing cardiovascular disease.
The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
The research team plans to collect data characterizing upper airway anatomy, motion, and airflow. In patients, these data may be recorded before and after surgery. The data may include some or all of the following: (1) Static and dynamic proton MRI of the airway. (2) Respiratory airflow measurements. (3) Data from clinical PSGs. (5) Measurements may be repeated at different levels of CPAP.